Recently, Eharmony Pharma announced the completion of its nearly RMB 100 million Series B financing round. This round was led by Beijing Medical and Health Industry Investment Fund, with participation from follow-on investors including Sanze Ventures and other institutions. The funds will be focused on three core strategic areas: advancing clinical development of key pipeline candidates, building a world-leading peptide inhalable delivery platform, and accelerating the global layout of innovative products. These initiatives will comprehensively consolidate the company’s end-to-end competitive advantages in the field of dry powder inhaler (DPI) drug delivery.

Eharmony Pharma is a high-tech enterprise specialized in "drug-device combination dry powder inhaler (DPI) delivery innovation", integrating research and development (R&D), manufacturing, and sales. The company primarily focuses on the development of dry powder inhalable formulations for respiratory and cardio-cerebrovascular diseases, having established an integrated closed-loop system covering laboratory technology, industrial-scale production, and commercialization. The successful closing of this financing round not only reflects deep capital recognition of its technological strength and strategic layout but also marks the company’s entry into a new three-dimensional development phase characterized by "clinical acceleration, platform upgrading, and global expansion".

Picture: From Wechat Public Account GLP-1 Weight Loss Bible

Among its pipeline candidates, FD1016 is an innovative inhalable drug targeting weight loss. It delivers a triple-target peptide of GLP-1/GIP/GCG via dry powder inhalation, which enters the bloodstream through the lungs to achieve long-acting fat reduction. This formulation avoids the pain and injection sites associated with subcutaneous injections, offers a dozens of times higher bioavailability compared to similar oral products, requires no refrigeration, and exhibits superior stability over traditional injectables. It is classified as a First-in-Class (FIC) product.
FD4001: A fixed-dose combination dry powder inhaler for the treatment of asthma.
FD4014: A triple-combination dry powder inhaler for moderate to severe chronic obstructive pulmonary disease (COPD).
F2008: A modified new drug for idiopathic pulmonary fibrosis (IPF), a rare disease.
All four aforementioned products are developed based on the company’s end-to-end dry powder inhaler (DPI) delivery platform. The company has achieved full independent control over the entire process, from formulation design and device development to production line customization. This has shortened the development cycle by approximately 3–5 years compared to the industry average, delivering significant cost advantages and comprehensive coverage of high-priority clinical indications including asthma, COPD, IPF, and weight management.